FHAB Advantage Sonnet's Fully Human Albumin Binding (FHAB) platform extends systemic exposure and improves delivery to inflammation sites and tumors by hitchhiking on albumin, enabling potentially more durable responses and easier combinations with other biologics. This positions FHAB as a value proposition for licensing or co-development with oncology and inflammatory-disease partners seeking enhanced PK and targeted delivery.

Active Pipeline Opportunities Lead asset SON-1010 and late preclinical SON-080 offer near-term collaboration opportunities for co-development, licensing, or joint ventures. Positive early data and recent conference presentations can support partner-led expansion into additional tumor types or inflammatory indications.

Regional Partnership Potential The Alkem Laboratories deal demonstrates appetite for regional commercialization, suggesting multiple geographic licensing or co-development arrangements in high-potential markets such as India and other emerging regions to monetize the platform and pipeline.

Cross-Sector Applications Although primarily focused on immune oncology, the FHAB platform’s mechanism could be applied to other cytokines and biologics across therapeutic areas, inviting partnerships with diverse biologics developers seeking improved half-life and tissue targeting.

Funding and Commercial Readiness With a small team and minimal current revenue, Sonnet appears well-positioned for partner-driven funding and milestone-based deals. A BD strategy could emphasize upfronts, development milestones, and royalty streams tied to program progression, reducing internal capital needs while delivering value to partners.